Unknown

Dataset Information

0

Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion.


ABSTRACT:

Background

Recent studies have demonstrated that blocking the PI3Kδ signalling enzyme (by administering a small molecule inhibitor, PI-3065) can potently improve the anti-tumour T-cell response through direct inhibition of Tregs. This treatment also has a negative impact on MDSC numbers but the primary mechanism driving this effect has remained unclear.

Methods

The 4T1 breast cancer mouse model was used in combination with PI-3065 to gain insights into the effect of PI3Kδ inhibition on MDSCs.

Results

PI-3065 treatment resulted in a concomitant reduction in MDSC expansion and tumour size. However, targeting Tregs independent of PI-3065 was also associated with reduced tumour volume and MDSC numbers. Surgical removal of tumours resulted in a rapid and significant decline in MDSC numbers, whilst ex vivo studies using cells from PI-3065-treated mice demonstrated no direct effect of the inhibitor on MDSC activity.

Conclusions

Our data suggest that MDSCs are not inhibited directly by PI-3065 treatment but that their reduced recruitment and immunosuppression within the tumour microenvironment is an indirect consequence of PI3Kδ-inhibition-driven tumour control. This indicates that PI3Kδ inhibition drives tumour immunity by breaking down multiple immunosuppressive pathways through both direct mechanisms (on Treg) and indirect mechanisms, secondary to tumour control (on MDSCs).

SUBMITTER: Lauder SN 

PROVIDER: S-EPMC9596434 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion.

Lauder Sarah N SN   Smart Kathryn K   Bart Valentina M T VMT   Pires Ana A   Scott Jake J   Milutinovic Stefan S   Godkin Andrew A   Vanhaesebroeck Bart B   Gallimore Awen A  

British journal of cancer 20220819 9


<h4>Background</h4>Recent studies have demonstrated that blocking the PI3Kδ signalling enzyme (by administering a small molecule inhibitor, PI-3065) can potently improve the anti-tumour T-cell response through direct inhibition of Tregs. This treatment also has a negative impact on MDSC numbers but the primary mechanism driving this effect has remained unclear.<h4>Methods</h4>The 4T1 breast cancer mouse model was used in combination with PI-3065 to gain insights into the effect of PI3Kδ inhibiti  ...[more]

Similar Datasets

| S-EPMC9573970 | biostudies-literature
2022-10-26 | GSE210910 | GEO
| 2381881 | ecrin-mdr-crc
| S-EPMC5466078 | biostudies-literature
| S-EPMC8898356 | biostudies-literature
| PRJNA868308 | ENA
| S-EPMC10266145 | biostudies-literature
| S-EPMC7591715 | biostudies-literature
| S-EPMC4046249 | biostudies-literature
| S-EPMC4884142 | biostudies-literature